Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China | |
Gu, Xiaohua; Zhang, Qiang; Chu, Yun-Bo; Zhao, Yi-Yang; Zhang, Yan-Jun; Kuo, David; Su, Betty; Wu, Bin | |
刊名 | LUNG CANCER |
2019 | |
卷号 | Vol.127页码:84-89 |
关键词 | Afatinib EGFR mutation Cost-effectiveness Non-small cell lung cancer |
ISSN号 | 0169-5002 |
URL标识 | 查看原文 |
公开日期 | [db:dc_date_available] |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/4744707 |
专题 | 湖南大学 |
作者单位 | 1.Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Resp Med, Shanghai, Peoples R China 2.Shanghai Univ Tradit Chinese Med, Putuo Hosp, Dept Oncol, Shanghai, Peoples R China 3.Boehringer Ingelhe China Investment Co Ltd, Shanghai, Peoples R China 4.Boston Healthcare, Shanghai, Peoples R China 5.Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Med Decis & Econ Grp,Dept Pharm, Shanghai, Peoples R China |
推荐引用方式 GB/T 7714 | Gu, Xiaohua,Zhang, Qiang,Chu, Yun-Bo,et al. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China[J]. LUNG CANCER,2019,Vol.127:84-89. |
APA | Gu, Xiaohua.,Zhang, Qiang.,Chu, Yun-Bo.,Zhao, Yi-Yang.,Zhang, Yan-Jun.,...&Wu, Bin.(2019).Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.LUNG CANCER,Vol.127,84-89. |
MLA | Gu, Xiaohua,et al."Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China".LUNG CANCER Vol.127(2019):84-89. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论